Cognitive-behavioral therapy in the treatment of patients with chronic migraine and emotional impairment: A prospective randomized trial with a two-year follow-up period
Abstract
Background. Among patients with chronic migraine (CM), emotional disorders (anxiety, depression) are common, promoting the chronic course of migraine and making treatment challenging. Cognitive behavioral therapy (CBT) is promising in the complex treatment of patients with CM and emotional disorders. However, few randomized studies have been conducted to assess the effectiveness of CBT in this category of patients.
Aim. To evaluate the effectiveness of an interdisciplinary program, including CBT, in the treatment of patients with CM and emotional disorders (anxiety, depression).
Materials and methods. The study included 176 patients with CM and emotional disorders (55 males and 121 females), mean age 36.2 ±8.7 years. All patients underwent clinical interviews, neurological examinations, and testing using clinical and psychological techniques. Patients were randomized into two groups: Group 1 received the standard of care (preventive and acute treatment pharmacotherapy, lifestyle recommendations, physical activity during the day, detoxification therapy in the presence of drug-induced headache – HA) and CBT in the form of 10 individual face-to-face sessions aimed at treating pain, improving emotional state and daily activity; Group 2 received only the standard of care. All patients were evaluated for clinical and psychological parameters before treatment and at 3, 6, 12, and 24 months after the start of treatment.
Results. After 3 months of treatment, a statistically…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 176 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.